Monopar Therapeutics initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of Monopar Therapeutics (MNPR) with a Buy rating and $71 price target Monopar is developing a Phase 3 drug for Wilson disease and radiopharmaceuticals to directly target tumors with minimal systemic side effects, the analyst tells investors in a research note. The firm assumes ALXN-1840 could be approved in 2026 and launched in 2027 in the U.S.. In 2035, the drug could achieve about $220M in sales in the U.S., contends Lucid.